Download Estrogens And Progestogens In Clinical Practice full books in PDF, epub, and Kindle. Read online Estrogens And Progestogens In Clinical Practice ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
This book provides a comprehensive approach to an understanding of all clinical conditions where estrogens and progestogens are involved. It encompasses the underlying science of chemistry, physiology, biochemistry and pharmacology. There is a broad but detailed perspective on the clinical use of estrogens and progestogens in therapy, contraception and hormone replacement therapy. An international line up of contributors provide an up-to-date world view on this subject.
Book Synopsis Estrogens and Progestogens in Clinical Practice by : Ian S. Fraser
Download or read book Estrogens and Progestogens in Clinical Practice written by Ian S. Fraser and published by . This book was released on 1998 with total page 944 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive approach to an understanding of all clinical conditions where estrogens and progestogens are involved. It encompasses the underlying science of chemistry, physiology, biochemistry and pharmacology. There is a broad but detailed perspective on the clinical use of estrogens and progestogens in therapy, contraception and hormone replacement therapy. An international line up of contributors provide an up-to-date world view on this subject.
These two volumes on Estrogens, Progestins, and Their Antagonists repre sent a thematic extension of the series, Hormones in Health and Disease. The first publication in the series, Steroid Hormone Receptors: Basic and Clinical Aspects, focused on recent advances in the anatomy of steroid receptors and members of the steroid receptor superfamily. Consistent with the spirit of the series, the authors addressed issues of clinical significance of steroid receptor detection in hormone-related disorders. The second volume in the series, Hormones and Cancer, attempted a more direct examination of ac tions of hormones in cancerous tissues and cells. In these two volumes, which together form the third in the series, the editor, Dr. Edward Pavlik, has introduced a team of leading investigators engaged in research on various aspects of the steroids that regulate female reproductive physiology. Estrogens and progestins, the main components of the most widely used contraceptive pills, have found a variety of uses in clinical endocrinology. These volumes contain discussions that range from the introduction of novel hormonal ligands to "hormonal antagonism by steroid analogs. A balanced treatment is provided of applications of the steroids in treatment and management of hormone-dependent conditions and malignancies. The remarkable synthesis of literature contained in this volume will provide a reader with both the fundamental concepts underly ing steroid hormone physiology and the clinical applications of observations made on basic aspects of hormone action. I congratulate the editorial leadership of Dr.
Book Synopsis Estrogens, Progestins, and Their Antagonists by : Edward J. Pavlik
Download or read book Estrogens, Progestins, and Their Antagonists written by Edward J. Pavlik and published by Birkhäuser. This book was released on 2012-11-19 with total page 248 pages. Available in PDF, EPUB and Kindle. Book excerpt: These two volumes on Estrogens, Progestins, and Their Antagonists repre sent a thematic extension of the series, Hormones in Health and Disease. The first publication in the series, Steroid Hormone Receptors: Basic and Clinical Aspects, focused on recent advances in the anatomy of steroid receptors and members of the steroid receptor superfamily. Consistent with the spirit of the series, the authors addressed issues of clinical significance of steroid receptor detection in hormone-related disorders. The second volume in the series, Hormones and Cancer, attempted a more direct examination of ac tions of hormones in cancerous tissues and cells. In these two volumes, which together form the third in the series, the editor, Dr. Edward Pavlik, has introduced a team of leading investigators engaged in research on various aspects of the steroids that regulate female reproductive physiology. Estrogens and progestins, the main components of the most widely used contraceptive pills, have found a variety of uses in clinical endocrinology. These volumes contain discussions that range from the introduction of novel hormonal ligands to "hormonal antagonism by steroid analogs. A balanced treatment is provided of applications of the steroids in treatment and management of hormone-dependent conditions and malignancies. The remarkable synthesis of literature contained in this volume will provide a reader with both the fundamental concepts underly ing steroid hormone physiology and the clinical applications of observations made on basic aspects of hormone action. I congratulate the editorial leadership of Dr.
This document is one of two evidence-based cornerstones of the World Health Organization's (WHO) new initiative to develop and implement evidence-based guidelines for family planning. The first cornerstone, the Medical eligibility criteria for contraceptive use (third edition) published in 2004, provides guidance for who can use contraceptive methods safely. This document, the Selected practice recommendations for contraceptive use (second edition), provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. The recommendations contained in this document are the product of a process that culminated in an expert Working Group meeting held at the World Health Organization, Geneva, 13-16 April 2004.
Book Synopsis Selected Practice Recommendations for Contraceptive Use by : World Health Organization. Reproductive Health and Research
Download or read book Selected Practice Recommendations for Contraceptive Use written by World Health Organization. Reproductive Health and Research and published by World Health Organization. This book was released on 2005 with total page 144 pages. Available in PDF, EPUB and Kindle. Book excerpt: This document is one of two evidence-based cornerstones of the World Health Organization's (WHO) new initiative to develop and implement evidence-based guidelines for family planning. The first cornerstone, the Medical eligibility criteria for contraceptive use (third edition) published in 2004, provides guidance for who can use contraceptive methods safely. This document, the Selected practice recommendations for contraceptive use (second edition), provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. The recommendations contained in this document are the product of a process that culminated in an expert Working Group meeting held at the World Health Organization, Geneva, 13-16 April 2004.
Progestogens are a class of steroid hormones that bind to and activate the progesterone receptor. This book is a guide to the use of progestogens for clinicians. Beginning with an overview of structure, biochemistry and classification, the following chapters discuss methods of administration, pharmacokinetics, metabolism and the physiological actions of progesterone. The remaining sections of the book cover clinical usage guidelines for progestogens, their role in contraception, side effects and contraindications. The book concludes with a chapter offering guidance on prescription writing and detailed references. Key points Guide to progestogens for obstetricians and gynaecologists Provides step by step detail on structure, classification, and pharmacokinetics Includes clinical usage guidelines, side effects and contraindications Features chapter on prescription writing
Book Synopsis Use of Progestogens in Clinical Practice of Obstetrics and Gynecology by : Anita MV
Download or read book Use of Progestogens in Clinical Practice of Obstetrics and Gynecology written by Anita MV and published by JP Medical Ltd. This book was released on 2018-07-31 with total page 108 pages. Available in PDF, EPUB and Kindle. Book excerpt: Progestogens are a class of steroid hormones that bind to and activate the progesterone receptor. This book is a guide to the use of progestogens for clinicians. Beginning with an overview of structure, biochemistry and classification, the following chapters discuss methods of administration, pharmacokinetics, metabolism and the physiological actions of progesterone. The remaining sections of the book cover clinical usage guidelines for progestogens, their role in contraception, side effects and contraindications. The book concludes with a chapter offering guidance on prescription writing and detailed references. Key points Guide to progestogens for obstetricians and gynaecologists Provides step by step detail on structure, classification, and pharmacokinetics Includes clinical usage guidelines, side effects and contraindications Features chapter on prescription writing
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
Book Synopsis Hormonal Contraception and Post-menopausal Hormonal Therapy by : IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Download or read book Hormonal Contraception and Post-menopausal Hormonal Therapy written by IARC Working Group on the Evaluation of Carcinogenic Risks to Humans and published by World Health Organization. This book was released on 1999 with total page 692 pages. Available in PDF, EPUB and Kindle. Book excerpt: Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
Book Synopsis Estrogens, Progestins, and Their Antagonists by : Edward J. Pavlik
Download or read book Estrogens, Progestins, and Their Antagonists written by Edward J. Pavlik and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 339 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Menopause and Hormone Replacement by : Hilary O. D. Critchley
Download or read book Menopause and Hormone Replacement written by Hilary O. D. Critchley and published by . This book was released on 2004 with total page 364 pages. Available in PDF, EPUB and Kindle. Book excerpt:
This comprehensive ready-reference guide thoroughly examines the physiological aspects of progestins and their role at the receptor level, focusing on reproductive activity, menopausal treatment, and related areas. The book presents vital research findings on the clinical use of progesterone and related derivatives, plus key applications of antiprogestins. Illuminates progesterone's remarkable power in hormonal contraception and regulation of the hypothalamo-pituitary complex! Written by more than 25 leading international experts on women's health, Progestins and Antiprogestins in Clinical Practice explains the effects of long-term controlled progestin studies on breast tissue discusses the nuclear localization of steroid hormone receptors covers the relationship of CDK activity and cell proliferation analyzes production of progesterone metabolites and precursors synthesized locally within the brain and in the endocrine glands describes cardiovascular effects associated with combined oral contraceptives (COCs), highlighting carbohydrate and lipid metabolism and hematological factors investigates the epidemiology of estrogen-induced endometrial hyperplasia and/or cancer demonstrates cases in which minor structural modifications in some steroid molecules can affect biological function explores several properties of progesterone and its natural derivatives illustrates instances of cloning of the intracellular progesterone receptor (PR) in several species assesses direct progesterone action in target tissues and indirect effects of progesterone regulation surveys properties of widely used contraceptive steroids, such as norethindrone (NET) plus estradiol (E2), levonorgestrel (LNG) plus estradiol (E2), nestorone plus ethinyl estradiol (EE2), and NET acetate plus EE2 reviews the efficacy and safety of newer contraceptive strategies such as Norplant implants and vaginal rings covers applications of RU486 (mifepristone) and more!
Book Synopsis Progestins and Antiprogestins in Clinical Practice by : Daniel R. Mishell
Download or read book Progestins and Antiprogestins in Clinical Practice written by Daniel R. Mishell and published by CRC Press. This book was released on 1999-11-10 with total page 424 pages. Available in PDF, EPUB and Kindle. Book excerpt: This comprehensive ready-reference guide thoroughly examines the physiological aspects of progestins and their role at the receptor level, focusing on reproductive activity, menopausal treatment, and related areas. The book presents vital research findings on the clinical use of progesterone and related derivatives, plus key applications of antiprogestins. Illuminates progesterone's remarkable power in hormonal contraception and regulation of the hypothalamo-pituitary complex! Written by more than 25 leading international experts on women's health, Progestins and Antiprogestins in Clinical Practice explains the effects of long-term controlled progestin studies on breast tissue discusses the nuclear localization of steroid hormone receptors covers the relationship of CDK activity and cell proliferation analyzes production of progesterone metabolites and precursors synthesized locally within the brain and in the endocrine glands describes cardiovascular effects associated with combined oral contraceptives (COCs), highlighting carbohydrate and lipid metabolism and hematological factors investigates the epidemiology of estrogen-induced endometrial hyperplasia and/or cancer demonstrates cases in which minor structural modifications in some steroid molecules can affect biological function explores several properties of progesterone and its natural derivatives illustrates instances of cloning of the intracellular progesterone receptor (PR) in several species assesses direct progesterone action in target tissues and indirect effects of progesterone regulation surveys properties of widely used contraceptive steroids, such as norethindrone (NET) plus estradiol (E2), levonorgestrel (LNG) plus estradiol (E2), nestorone plus ethinyl estradiol (EE2), and NET acetate plus EE2 reviews the efficacy and safety of newer contraceptive strategies such as Norplant implants and vaginal rings covers applications of RU486 (mifepristone) and more!
Medical Eligibility Criteria for Contraceptive Use reviews the medical eligibility criteria for use of contraception, offering guidance on the safety and use of different methods for women and men with specific characteristics or known medical conditions. The recommendations are based on systematic reviews of available clinical and epidemiological research. It is a companion guideline to Selected Practice Recommendations for Contraceptive Use. Together, these documents are intended to be used by policy-makers, program managers, and the scientific community to support national programs in the preparation of service delivery guidelines. The fourth edition of this useful resource supersedes previous editions, and has been fully updated and expanded. It includes over 86 new recommendations and 165 updates to recommendations in the previous edition. Guidance for populations with special needs is now provided, and a new annex details evidence on drug interactions from concomitant use of antiretroviral therapies and hormonal contraceptives. To assist users familiar with the third edition, new and updated recommendations are highlighted. Everyone involved in providing family planning services and contraception should have the fourth edition of Medical Eligibility Criteria for Contraceptive Use at hand.
Book Synopsis Medical Eligibility Criteria for Contraceptive Use by :
Download or read book Medical Eligibility Criteria for Contraceptive Use written by and published by World Health Organization. This book was released on 2010 with total page 130 pages. Available in PDF, EPUB and Kindle. Book excerpt: Medical Eligibility Criteria for Contraceptive Use reviews the medical eligibility criteria for use of contraception, offering guidance on the safety and use of different methods for women and men with specific characteristics or known medical conditions. The recommendations are based on systematic reviews of available clinical and epidemiological research. It is a companion guideline to Selected Practice Recommendations for Contraceptive Use. Together, these documents are intended to be used by policy-makers, program managers, and the scientific community to support national programs in the preparation of service delivery guidelines. The fourth edition of this useful resource supersedes previous editions, and has been fully updated and expanded. It includes over 86 new recommendations and 165 updates to recommendations in the previous edition. Guidance for populations with special needs is now provided, and a new annex details evidence on drug interactions from concomitant use of antiretroviral therapies and hormonal contraceptives. To assist users familiar with the third edition, new and updated recommendations are highlighted. Everyone involved in providing family planning services and contraception should have the fourth edition of Medical Eligibility Criteria for Contraceptive Use at hand.
